Rebound Therapeutics
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Stage
Acquired | AcquiredTotal Raised
$20.26MAbout Rebound Therapeutics
Rebound Therapeutics develops single-use medical devices that enable minimally invasive access, using optics and illumination, for visualization, diagnostic and therapeutic use in neurosurgery. Rebound's minimally invasive surgical (MIS) technology features integrated optics and illumination capable of interfacing with existing operating room monitors.
Rebound Therapeutics Headquarter Location
13900 Alton Parkway, Suite 120
Irvine, California, 92618,
United States
949-305-8111
Expert Collections containing Rebound Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Rebound Therapeutics is included in 3 Expert Collections, including Medical Devices.
Medical Devices
11,528 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
2,394 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Health IT
7,900 items
Rebound Therapeutics Patents
Rebound Therapeutics has filed 30 patents.
The 3 most popular patent topics include:
- Medical equipment
- Dosage forms
- Neurotrauma
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/20/2020 | 7/5/2022 | Neurotrauma, Medical equipment, Dosage forms, Neurosurgery, Drug delivery devices | Grant |
Application Date | 7/20/2020 |
---|---|
Grant Date | 7/5/2022 |
Title | |
Related Topics | Neurotrauma, Medical equipment, Dosage forms, Neurosurgery, Drug delivery devices |
Status | Grant |
Latest Rebound Therapeutics News
Jul 27, 2022
Major players in the hydrocephalus market are Christoph Miethke GmbH & Co. KG, Medtronic Plc, Sophysa, Tokibo Co. Ltd. , Spiegelberg GmbH & Co. KG. , B. Braun Melsungen AG, Alcyone Therapeutics Inc. July 27, 2022 13:30 ET Lyon, FRANCE New York, July 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hydrocephalus Global Market Report 2022" - https://www.reportlinker.com/p06310153/?utm_source=GNW , Natus Medical Incorporated, HpBio Proteses Inc., Surgiwear Ltd., and Kaneka Medix Corporation. The global hydrocephalus market is expected to grow from $3.12 billion in 2021 to $3.26 billion in 2022 at a compound annual growth rate (CAGR) of 4.2%. The hydrocephalus market is expected to grow to $3.84 billion in 2026 at a CAGR of 4.2%. The hydrocephalus market consists of sales of hydrocephalus devices (organizations, sole traders, and partnerships) that are used for the treatment of hydrocephalus.Hydrocephalus is a medical condition in which the cerebrospinal fluid (CSF) that commonly passes through the spaces of the brain and spinal column in normal circumstances starts accumulating in the cavities of brain structures, resulting in a variety of cognitive abnormalities. Head enlargement is an indication of hydrocephalus in infants. The various symptoms of hydrocephalus are headaches, blurred vision, cognitive impairments, loss of coordination, and incontinence. The main types of hydrocephalus are congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus, ex-vacuo hydrocephalus.Congenital hydrocephalus is caused by a birth abnormality or brain malformation that causes excessive cerebrospinal fluid (CSF) to build in the subarachnoid space of the brain. Hydrocephalus can be in paediatric or adult and can be detected using MRI, CT scan, head ultrasound, others. There are various end users of hydrocephalus such as hospitals, diagnostic centres, academic institutions, research organizations. North America was the largest region in the hydrocephalus market in 2021. The regions covered in the hydrocephalus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The hydrocephalus market research report is one of a series of new reports that provides hydrocephalus market statistics, including hydrocephalus industry global market size, regional shares, competitors with a hydrocephalus market share, detailed hydrocephalus market segments, market trends and opportunities, and any further data you may need to thrive in the hydrocephalus industry. This hydrocephalus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The increased prevalence of hydrocephalus is significantly contributing to the growth of the hydrocephalus market.Hydrocephalus is a medical condition in which the cerebrospinal fluid (CSF) starts accumulating in the cavities of brain structures, resulting in a variety of cognitive abnormalities. The increasing incidences of hydrocephalus are increasing the demand for hydrocephalus treatment devices to treat the patients.For instance, according to a 2021 report published in the National Center for Biotechnology Information, a part of the United States National Library of Medicine, a branch of the National Institutes of Health, the global prevalence of hydrocephalus is reported to be around 85 per 100,000 people, with a notable disparity between age groups 88 per 100,000 in children and 11 per 100,000 in adults. The prevalence is substantially higher in the senior population, around 175 per 100,000, and more than 400 per 100,000 for those over 80 years old. Therefore, increased prevalence of hydrocephalus is expected to propel the growth of the hydrocephalus market. Technological advancements are the key trends gaining popularity in the hydrocephalus market.The major players in the market are developing advanced technological hydrocephalus devices for the treatment of hydrocephalus. For instance, in June 2021, Cranial Devices Inc., a US-based start-up from Pennsylvania State University advanced a device named HydroFix, a high-tech shunt system that involves a CSF drain to improve the treatment of hydrocephalus. HydroFix technology will address the significant unmet clinical needs of reducing the risks related to surgical shunts failure. In September 2019, Integra LifeSciences Holdings Corporation, a US-based medical device manufacturing company acquired Rebound Therapeutics for an undisclosed amount.Through this acquisition, Integra Lifescience will increase its portfolio of neurosurgical products and therapeutic-focused capabilities to develop innovative products to address neurosurgery needs. Rebound Therapeutics is a US-based company that designs medical devices for a variety of surgical procedures including neurosurgery. The countries covered in the hydrocephalus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
Where is Rebound Therapeutics's headquarters?
Rebound Therapeutics's headquarters is located at 13900 Alton Parkway, Suite 120, Irvine.
What is Rebound Therapeutics's latest funding round?
Rebound Therapeutics's latest funding round is Acquired.
How much did Rebound Therapeutics raise?
Rebound Therapeutics raised a total of $20.26M.
Who are the investors of Rebound Therapeutics?
Investors of Rebound Therapeutics include Integra LifeSciences, Invus Group, Wexford Capital and HBM Healthcare Investments.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.